Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

NCT04599556 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

81

Enrollment

OTHER

Sponsor class

Conditions

CD7+ Acute Leukemia
CD7+ Lymphoma

Interventions

BIOLOGICAL: anti-CD7 CAR-T

Sponsor

Zhejiang University

Collaborators

[object Object]